NCI-9030 was a Phase I dose-escalation study of intravenously-administered REOLYSIN® alone in patients with relapsed or refractory multiple myeloma. Patients received REOLYSIN® on days 1 through 5 of each twenty-eight day treatment cycle for up to twelve cycles in the absence of disease progression or unacceptable toxicity. Approximately twelve response evaluable patients were enrolled. The primary objectives were toxicity and maximum-tolerated dose level. Secondary objectives included duration of response, objective response rate, progression-free survival and time to progression.
Findings from the study were presented at the 15th Annual International Myeloma Workshop (IMW) in September 2015, disclosing that the treatment was safe and well tolerated.
The study was sponsored and conducted by the US National Cancer Institute (NCI).